Barclays
TTPH

Barclays’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Barclays’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,525
Closed -$34K – 7373
2019
Q2 		$34K Buy
3,525
+913
+35% +$16.8K ﹤0.01% 6259
2019
Q1 		$70K Buy
2,612
+1,724
+194% +$43.9K ﹤0.01% 5644
2018
Q4 		$20K Sell
888
-1,301
-59% -$50.9K ﹤0.01% 5909
2018
Q3 		$121K Buy
2,189
+1,995
+1,028% +$127K ﹤0.01% 5393
2018
Q2 		$14K Sell
194
-1,381
-88% -$97.5K ﹤0.01% 6391
2018
Q1 		$97K Sell
1,575
-1,897
-55% -$167K ﹤0.01% 5410
2017
Q4 		$438K Sell
3,472
-2,051
-37% -$263K ﹤0.01% 3991
2017
Q3 		$756K Buy
5,523
+653
+13% +$87.3K ﹤0.01% 3252
2017
Q2 		$694K Sell
4,870
-802
-14% -$124K ﹤0.01% 3207
2017
Q1 		$1.04M Buy
5,672
+3,988
+237% +$447K ﹤0.01% 2699
2016
Q4 		$136K Buy
1,684
+1,673
+15,209% +$132K ﹤0.01% 4528
2016
Q3 		$1K Sell
11
-16
-59% -$1.28K ﹤0.01% 6509
2016
Q2 		$2K Sell
27
-593
-96% -$54.3K ﹤0.01% 6016
2016
Q1 		$50K Buy
620
+306
+97% +$30.6K ﹤0.01% 4766
2015
Q4 		$63K Sell
314
-682
-68% -$136K ﹤0.01% 4667
2015
Q3 		$139K Buy
996
+429
+76% +$315K ﹤0.01% 4396
2015
Q2 		$532K Buy
567
+8
+1% +$6.54K ﹤0.01% 3422
2015
Q1 		$403K Sell
559
-341
-38% -$256K ﹤0.01% 3793
2014
Q4 		$703K Buy
900
+863
+2,332% +$465K ﹤0.01% 3524
2014
Q3 		$14K Buy
37
+17
+85% +$4.55K ﹤0.01% 6715
2014
Q2 		$5K Sell
20
-1,017
-98% -$218K ﹤0.01% 7143
2014
Q1 		$207K Buy
1,037
+1,022
+6,813% +$285K ﹤0.01% 4759
2013
Q4 		$3K Sell
15
-7
-32% -$1.67K ﹤0.01% 7298
2013
Q3 		$5K Sell
22
-8
-27% -$1.4K ﹤0.01% 7001
2013
Q2 		$4K Buy
+30
New +$4.75K ﹤0.01% 7425

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barclays's TTPH Position: Q3 2019 in Review

Barclays sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 3,525 shares — an estimated $34K sold.

Barclays first reported a position in TTPH in Q2 2013 and held it in 25 quarters. The position peaked at $1.04M in Q1 2017. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

  • Barclays reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Barclays sold 3,525 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $34K.
  • Barclays first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
  • Barclays's Tetraphase Pharmaceuticals, Inc. position peaked at $1.04M in Q1 2017.
  • 26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Barclays's 13F filing for Q3 2019, filed 14 Nov 2019.